



Health Robotics

Health Robotics announces immediate availability of IV Robot for newest hazardous drug class: Monoclonal Antibodies Therapy.

BOZEN, SUD-TIROL, 18th August 2008.

Health Robotics, the worldwide leader in the Robotic Automation of patient-specific IV Admixtures, today announced that four (4) hospitals in Europe and one (1) in the United States have successfully and repeatedly validated the company's unique and proprietary Robotics technology to support the sterile, just-in-time, accurate, safe, efficient, and ready-to-administer preparation, compounding and dispensing of patient-specific IV medications for an additional hazardous drug class: Monoclonal Antibodies (mAbs) Therapy.

"Successful patient utilization of our IV Robotic solutions to include mAb Therapy is a huge step for our company, our customers, and the industry in general. Prior to these independent validations, Health Robotics was the only company in the world that offered an IV Robotics solution proven in hospitals to produce chemotherapy IV doses. Now we not only add to our unique leadership position within Oncology Pharmacy by supporting cancer-related mAb-Therapy, but at the same time we are able to expand our Robotics solutions into other health-care areas such as Crohn's Disease, Organ Transplants, Multiple Sclerosis, Rheumatoid Arthritis, and other Infectious Diseases, Cardiovascular, Haematology, and Autoimmune and Inflammatory Disorders", stated Werner Rainer, CEO of Health Robotics.

As many as five (5) Market Intelligence and Research companies have recently spotlighted Monoclonal Antibodies' current explosive growth and their immense future potential.

Frost & Sullivan: "Monoclonal Antibodies (mAbs) are currently the hot property in the pharmaceutical space. Termed as "magic bullets", they really deserved to be called so, considering the therapeutic and financial success of these products. Superior side effect profile and high target specificity are the key attributes for their instant success in the market. Currently valued at \$7.90 billion, the European therapeutic monoclonal antibody market is growing strong and steadily and forecasted to reach \$22.24 billion in 2014 at a CAGR of 16.6 per cent from 2008 to 2014." 13th June 2008.

Datamonitor: "mAbs are a high-performance segment of the pharmaceutical market, promising a 2007-2013 CAGR of 10.9%, a three-fold revenue premium over small molecules and immunity from material generic threat for the foreseeable future. There are two distinct groups of mAbs, the Big 5 and the Emerging 8, which together will shape the future of the mAb market. The Big 5 will continue to dominate the mAb landscape and will ensure the primary focus remains in oncology and immunology & inflammation. In contrast, the Emerging 8 will inject the mAb segment with growth and drive therapeutic diversification into cardiovascular and musculoskeletal disorders." 6th June 2008.



Health Robotics

The National Oncology Institute of Rome, Bozen General Hospital, Opus Dei Campus Biomedico University Hospital, Umberto I University Hospital's Immunology Department, and the University of Colorado Hospital at Denver successfully validated the automatic preparation and compounding of Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab), Mylotarg (gemtuzumab ozogamicin), and Rituxan (rituximab) [a.k.a. MabThera in Europe] with Health Robotics' automated Robotics and software solutions. While the first five (5) mAb compounds listed above are used in Oncology, Rituxan has been FDA-approved for dual utilization in Oncology and Rheumatoid Arthritis patients.

Continued Werner Rainer, CEO of Health Robotics. "When we looked at the challenges of compounding and dispensing mAb intravenous medications, we saw startling similarities with some chemotherapy drugs in the areas of high cost [vial re-use, high unit price, and lack of generic alternatives], drug stability timeline after compounding, light-sensitivity, powder reconstitution issues, complicated calculations, complex methods, and patient safety issues for these hazardous drugs. These issues coupled with the exponential growth of mAbs and the fact that they enable Health Robotics to move into non-Oncology patient-care areas made us decide that this was one of the fields where we should focus our efforts over the past three months. Now that our work and mAb success has been independently validated by hospitals, it is time for us to roll-out our mAb Robotic solutions worldwide."

Just like Health Robotics' recently announced non-hazardous drug robot IV Station™, Health Robotics will directly market, install, and support its Monoclonal Antibodies Robotic and software automated solutions while the company seeks and negotiates regional and/or global partners for its distribution, manufacturing, installation, and support activities.

About Health Robotics:

Health Robotics is the global leading supplier in the total automation of the processes for preparation, compounding, and dispensing of life-critical, intravenous, patient-specific, and ready-to-administer medications, providing health care facilities around the world with Robotics and software automation solutions. Health Robotics' world-leading Robotic solutions CytoCare™ (for hazardous IV medications) and IV Station™ (for non-hazardous IV drugs) have and will greatly contribute to ease global pharmacies' growing pressures to improve patient safety through the safe, effective, and efficient production of sterile, just-in-time, accurate, and ready-to-administer IVs, to decrease life-threatening medication errors, sterility and contamination risks, and to work more efficiently, increase throughput, reduce waste, and contain spiralling medication expenses.

For additional information, please contact:

Health Robotics

Gaspar G. DeViedma

Europe: +39 (346) 963-4934

North America: +1 (609) 980-797

gaspar.devedma@health-robotics.com